8-K: P3 Health Partners Reports Q2 Loss, Eyes 2026 Profitability

P3 Health Partners announced a Q2 2025 net loss of $43.7 million and a 6% revenue decline, but highlighted flat medical costs and significant 2026 EBITDA opportunities.

Summary

• P3 Health Partners Inc. reported financial results for the second quarter ended June 30, 2025, showing a net loss of $43.7 million.
• Total revenue for Q2 2025 was $355.8 million, a 6% decrease compared to the prior year's second quarter.
• Average at-risk membership decreased by 9% to approximately 115,000 members, attributed to previously disclosed network and payer rationalization.
• Medical margin was $30.6 million, or $89 PMPM, for Q2 2025.
• Adjusted EBITDA loss for Q2 2025 was $17.1 million, or $50 PMPM.
• The company adjusted its full-year 2025 guidance, reflecting prior-period adjustments and underperformance from a single payer.
• Revised Fiscal 2025 Guidance: At-risk Members between 109,000 and 119,000; Total Revenues between $1,350 million and $1,500 million; Medical Margin between $124 million and $154 million; Adjusted EBITDA loss between $39 million and $69 million.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant declines in membership and revenue, coupled with increased losses in the current quarter and a downward revision of full-year guidance. While management highlights positive future outlook and cost management, the immediate financial performance is concerning, and the identified risks are substantial.

Positives

• Successfully managed medical cost trends to remain flat despite industry inflation.
• Funding across membership improved by 10% on a per-member basis, when adjusted for prior-period items.
• Identified an additional $120 million to $170 million in EBITDA opportunities for 2026.
• Three of the four markets are already EBITDA positive or breakeven.
• Management believes the company is well-positioned to achieve sustained profitability in 2026 and beyond.
• Executing on a $130 million EBITDA improvement plan.

Negatives

• Average at-risk membership decreased by 9% to approximately 115,000 members compared to the prior year.
• Total revenue decreased by 6% to $355.8 million compared to the second quarter of the prior year.
• Medical margin decreased to $30.6 million ($89 PMPM) in Q2 2025 from $41.089 million ($107 PMPM) in Q2 2024.
• Adjusted EBITDA loss worsened to $17.1 million ($50 PMPM) in Q2 2025 from $8.847 million ($23 PMPM) in Q2 2024.
• Net loss increased to $43.665 million in Q2 2025 from $28.774 million in Q2 2024.
• Adjusted full year guidance reflects impact from prior-period adjustments and underperformance of a single payer.
• Cash and restricted cash decreased from $44.102 million at the beginning of the six-month period to $39.327 million at June 30, 2025.
• Current portion of long-term debt increased to $80 million as of June 30, 2025, from $65 million as of December 31, 2024.
• Accumulated deficit worsened to $544.035 million as of June 30, 2025, from $503.193 million as of December 31, 2024.

Risks

• Ability to continue as a going concern.
• Potential need to raise additional capital to fund existing operations or develop/commercialize new services.
• Ability to achieve or maintain profitability.
• Ability to maintain compliance with debt covenants or obtain required waivers from lenders.
• Risk of non-cash charges for goodwill and/or other intangible asset impairment if management's assumptions change.
• Ability to identify and develop successful new geographies, physician partners, payors, and patients.
• Changes in market or industry conditions, regulatory environment, competitive conditions, and receptivity to services.
• Ability to fund growth and expand operations.
• Changes in laws and regulations applicable to the business.
• Ability to maintain relationships with health plans and other key payors.
• Impact of fluctuations in risk adjustments.
• Ability to establish and maintain effective internal controls and the impact of identified material weaknesses.
• Ability to maintain the listing of securities on Nasdaq.
• Increased labor costs and medical expense.
• Ability to recruit and retain qualified team members and independent physicians.

Future Outlook

Management anticipates sustained profitability in 2026 and beyond, supported by an additional $120 million to $170 million in identified EBITDA opportunities for 2026. The company's revised fiscal 2025 guidance reflects the impact of prior-period adjustments and underperformance from a single payer.

Management Comments

• "Our core business continues to strengthen as we execute on our $130 million EBITDA improvement plan."
• "While we faced prior period headwinds, we've successfully managed medical cost trends to remain flat while improving funding across our membership on a per-member basis."
• "With an additional $120 to $170 million in identified EBITDA opportunities and three of our four markets already EBITDA positive or breakeven, P3 is well-positioned to achieve sustained profitability in 2026 and beyond."

Industry Context

P3 Health Partners operates in the population health management sector, a growing area focused on value-based care. The company's ability to manage medical cost trends to remain flat despite broader industry inflation suggests effective cost control strategies, which is a key differentiator in this competitive and cost-sensitive healthcare segment. The focus on achieving profitability in 2026 aligns with a broader industry trend of healthcare companies optimizing operations and seeking sustainable financial models amidst evolving regulatory and market pressures.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Negative impact from decreased revenue, increased losses, and downward revised guidance, potentially affecting share price. Future profitability projections offer a long-term positive outlook.
• Patients/Members: A 9% decrease in at-risk membership indicates a reduction in the patient base, likely due to network and payer rationalization.
• Employees: Severance expenses were incurred in connection with workforce reorganization, indicating potential job impacts.
• Creditors: Increased current portion of long-term debt and overall liabilities, along with a 'going concern' risk, could raise concerns about debt servicing ability.

Next Steps

• Host a conference call and webcast on August 14, 2025, at 4:30 PM ET to discuss Q2 2025 earnings.
• Continue executing on the $130 million EBITDA improvement plan.
• Work towards realizing the additional $120 million to $170 million in identified EBITDA opportunities for 2026.
• Focus on achieving sustained profitability in 2026 and beyond.

Key Dates

Recommendation

While the company reported significant declines in membership and revenue, alongside increased losses for the quarter and a downward revision of full-year guidance, management highlighted successful medical cost trend management and identified substantial EBITDA opportunities for 2026, projecting future profitability. The current period's underperformance is concerning, but the strategic initiatives and future outlook warrant a 'hold' to observe execution on the improvement plan and progress towards 2026 profitability targets before making a more definitive investment decision.

Keywords

P3 Health Partners, PIII, Q2 2025 earnings, financial results, population health management, value-based care, Medicare, EBITDA, medical margin, at-risk membership, healthcare, financial performance